A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Exclusion Criteria

• - Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months
• - Requires the use of drugs that stimulate gastrointestinal motility
• - Has been previously treated with Symlin (or has participated in a Symlin clinical study)
• - Is currently being treated with any of the following medications: *Over-the-counter antiobesity agents (including, but not limited to, herbal supplements) or prescription antiobesity agents (including orlistat [Xenical®] and sibutramine [Meridia®]); *Oral, intravenous, or intramuscular systemic steroids by oral or potent inhaled or intrapulmonary steroids that are known to have a high rate of systemic absorption; *Drugs that directly affect gastrointestinal motility, including but not limited to: dopamine antagonists (e.g., metoclopramide [Reglan®]), opiates or anticholinergics; and chronic (more than 10 days within a 6-month period) macrolide antibiotics such as erythromycin and newer derivatives; *Investigational medications
• - Has a history or presence of any of the following: *Eating disorders (including anorexia and/or bulimia); *Bariatric surgery (gastric bypass, gastric banding, or gastroplasty)
• - Is currently enrolled in a weight-loss program or plans to enroll in a weight-loss program before termination of the study
• - Has donated blood within 30 days of study start or plans to donate blood during the duration of the study